Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 EMD Millipore Acquires Singulex Technology | Contract Pharma

What are you searching for?

Sign in
Breaking News

EMD Millipore Acquires Singulex Technology

Acquires exclusive worldwide rights to SMC technology for research applications

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

EMD Millipore, the life science business of Merck KGaA of Darmstadt, Germany, and Singulex, the developer and provider of Single Molecule Counting (SMC) technology for clinical diagnostics and scientific discovery, have entered into an agreement under which EMD Millipore will control and manage the Singulex Life Science Research business. Under the terms of the agreement, EMD Millipore will pay Singulex an upfront payment, royalties and additional payments based upon achievement of certain commercial milestones. EMD Millipore will have exclusive rights to further develop and commercialize the SMC technology for research applications worldwide.

The SMC technology is a novel, patented technology combining signal enhancement and background reduction coupled with low volume sampling to achieve ultra-high sensitivity protein detection.

“This agreement is further evidence of EMD Millipore’s commitment to bringing innovative technologies to our global life science customers,” said Udit Batra, president and chief executive officer, EMD Millipore. “The Erenna platform offers the advantage of unrivaled sensitivity and precision and will be a strong addition to our protein detection franchise.”

“We are pleased with this strategic agreement with EMD Millipore since it puts our technology into the best possible hands to optimize its commercial scale-up and market potential,” said Guido Baechler, president and chief executive officer, Singulex. “This deal enables us to leverage our immunoassay technology to create additional opportunities in our other diagnostic businesses, especially within the area of companion diagnostics.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics